Back to results
US 2021/0071253 A1Published application
Heritable epigenetic modifications as markers of chemotherapy exposure
AssigneesWashington State University, Seattle Children's Hospital (dba Seattle Children's Research Institute)
InventorsMichael K. Skinner, Margarett Shnorhavorian
Life of this patent
Estimating the term…
Abstract
Provided herein are epigenetic modifications that are associated with prior exposure to chemotherapy agents. In particular, differential DNA methylation regions (DMRs) that are characteristic of, and can thus be used to identify and/or treat, a male subject who has undergone chemotherapy are provided. The DMRs are used to screen for pregnancy complications, infertility, and passage of heritable mutations to an infant.
Claims35
A method, comprising:
- obtaining a sperm sample from a subject;
- isolating a nucleic acid from at least a portion of said sperm sample;
- detecting a methylation alteration present in at least a portion of said nucleic acid comprising a differential DNA methylation region (DMR), wherein said DMR is listed in Table 10;
- and
- comparing said methylation alteration using a computer comprising one or more processors, one or more memories, and instructions disposed thereupon to a reference methylation alteration in a corresponding DMR listed in Table 10.
2 more elements
Dependencies are inferred from the claim text.